Corcept Therapeutics: FDA Approval of Lifyorli and the Path from CRL Devastation to Oncology Redemption

Executive Summary

In one of the most striking turnarounds in biotech over the past three months, Corcept Therapeutics has moved from potential extinction to validation of a core thesis. On March 25, 2026, the U.S. FDA approved Lifyorli™ (relacorilant) in combination with nab-paclitaxel for adults with platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic regimens. This is Corcept’s second commercially approved product and, more importantly, the first FDA-approved selective glucocorticoid receptor antagonist (SGRA) in oncology.

This approval comes exactly 12 weeks after the December 31, 2025 Complete Response Letter (CRL) that sent CORT plummeting 50% in a single day and raised serious questions about whether Corcept’s relacorilant program was a scientific and commercial mirage. It also arrives 5 weeks after the Federal Circuit affirmed that Corcept’s key Korlym patents do not prevent Teva’s generic, further pressuring the company’s legacy cash engine.

The stock opened up +40% on the approval news, erasing much of the CRL damage. But the narrative is now far more complex: Cushing’s syndrome access to relacorilant has been effectively closed off until Corcept runs a new trial (likely 3-5 years away), while ovarian cancer and emerging programs in MASH, ALS, and other indications are now in focus. The balance sheet remains strong (>$500M cash, profitable), but investor sentiment has fractured into those betting on Lifyorli’s oncology success and those worried about execution, dilution, and the class action lawsuits now pending against management.

Key Stats – CORT at a Turning Point

In summary, Corcept has moved from “one-product micro-cap facing existential questions” to “two-asset mid-cap with a validated oncology franchise, pending pipeline, and strong cash.” But the Cushing implosion leaves Corcept without the near-term revenue diversification it was banking on. Investors are betting that ovarian cancer and future programs can fill that gap. The next 12-24 months are the test.

The 12-Week Rollercoaster: From CRL Devastation to Redemption

To appreciate what today’s approval means, you need the full timeline. December 31, 2025 was supposed to be a victory lap: the FDA was set to make a decision on relacorilant in Cushing’s syndrome, based on the Phase 3 GRACE and GRADIENT trials. Instead, the agency issued a Complete Response Letter, saying it could not reach a favorable benefit-risk conclusion without additional evidence of effectiveness.

CORT dropped from ~$70 to ~$35 in a single day, wiping out ~50% of market cap. The message was clear: the FDA saw inconsistent efficacy across the two trials (one positive, one negative on primary endpoint), and the agency wanted proof of a more robust signal before approving.

Then, on February 19, 2026, the Federal Circuit issued a non-precedential opinion affirming that Teva’s generic Korlym does not infringe two key Corcept patents covering high-dose co-administration with CYP3A inhibitors. The stock dropped another 25.5% on that news, closing at $30.48. The implication was clear: Korlym’s long-term pricing power was effectively gone, and generic erosion would accelerate.

Now, March 25, 2026: FDA approves Lifyorli for ovarian cancer. The trial was successful, the data are solid, and the approval came early. The stock opens +40%, and much of the lost equity is recovered. It’s a stunning pivot.

The timeline reveals the real story: Corcept always had two shots on goal — Cushing and oncology — but investor focus was so locked on Cushing (because it was supposed to be near-term and large) that the ovarian cancer opportunity was treated as secondary. The CRL knocked Cushing off the board, the Federal Circuit nailed the legacy franchise, and now the market is finally repricing the company on what’s actually still alive: oncology, MASH, ALS, and the cash-generating Korlym business, even in generic form.

Lifyorli Approval: What the ROSELLA Data Actually Show

The ROSELLA Phase 3 trial enrolled 381 patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who had received one to three prior systemic treatment regimens, at least one including bevacizumab. Patients were randomized to receive relacorilant + nab-paclitaxel or nab-paclitaxel alone.

Primary Endpoints (Both Met)

• Overall Survival (OS): relacorilant + nab-paclitaxel resulted in a median OS of 16 months vs. 11.9 months on nab-paclitaxel alone. This translates to a 35% reduction in the risk of death (Hazard Ratio ≈0.65). The benefit was statistically significant and clinically meaningful.
• Progression-Free Survival (PFS): also met the primary endpoint with a meaningful improvement in progression-free survival, supporting the OS benefit.

Neither endpoint was expected to be a “home run” — ovarian cancer oncologists and payers work in a pragmatic world where a 4-month OS gain in a heavily pretreated population is considered valuable but not revolutionary. What matters is that relacorilant added that benefit without introducing additional toxicity beyond what chemotherapy already brings. The adverse event profile was consistent with expectations, and there were no shocking new safety signals.

Secondary and Exploratory Data

The trial also showed:

• Benefit in patients pre-treated with PARP inhibitors (a relevant subgroup).
• Manageable tolerability consistent with prior experience in other settings.
• No meaningful additional hepatotoxicity or other organ-specific concerns beyond known cortisol modulation effects.

Why This Matters for the Ovarian Market

Platinum-resistant ovarian cancer is a tough setting. Patients have often exhausted multiple prior lines of chemotherapy and targeted therapy (PARP inhibitors, bevacizumab). The median survival without new intervention hovers around 10–12 months. Adding a 4-month survival benefit with a well-tolerated drug is a meaningful advance. The FDA clearly agreed and approved on an accelerated timeline, suggesting the agency saw compelling clinical value.

Commercial opportunity is real: the platinum-resistant ovarian cancer patient population in the U.S. is estimated in the thousands per year, and payers are typically willing to reimburse for drugs with OS benefit, especially in late-line settings. Early analyst estimates suggest Lifyorli could generate $200–400M+ in annual peak sales in this indication alone, with potential for label expansion if BELLA (the multi-arm Phase 2) and other studies show benefit in earlier-line or broader gynecologic populations.

The Cushing Impasse: A 3–5 Year Detour

While Lifyorli is a win, Cushing is now a problem that won’t go away quickly. The December 31 CRL is not a one-time request for more data; it’s a structural setback that will require a new clinical trial, likely 3–5 years away from completion.

What Went Wrong in GRACE / GRADIENT

GRACE (the pivotal study) met its primary endpoint: patients with hypertension secondary to hypercortisolism showed meaningful improvements in blood pressure and hyperglycemia. GRADIENT, the confirmatory trial, did not. It failed its primary endpoint, which raised a red flag about the consistency and robustness of relacorilant’s benefit. The FDA essentially said: “We see signal in one trial, but we don’t see consistent evidence across both trials, and the patient population is heterogeneous (some have adrenal disease, some have pituitary disease). We need you to prove this works more broadly and robustly.”

Path Forward: New Trial Likely Required

In its February 2026 CRL communication, the FDA signaled that a new focused confirmatory trial would almost certainly be needed. This is different from a request for “re-analysis” or “additional post-hoc data.” A new trial means:

• Design work: Corcept and FDA must align on trial design, endpoints, patient population, and inclusion/exclusion criteria (likely 6–12 months).
• Recruitment and conduct: Patient enrollment, follow-up, and data lock (likely 18–36 months).
• Analysis and submission: Final analysis, regulatory submission (likely 6–12 months).
• Total timeline: 3–5 years, realistically.

This is not a death knell — endocrinologists still need relacorilant, and the Phase 3 data in Cushing (even with the GRACE/GRADIENT split) suggest real clinical benefit. But the near-term revenue opportunity is gone. Corcept will not launch relacorilant for Cushing in 2026 or likely 2027. It will depend on Korlym, Lifyorli, and pipeline programs (BELLA, MONARCH) to drive near-term cash and growth.

Management Commentary

CEO Joseph Belanoff has been characteristically measured, saying that Corcept will work with the FDA to understand the best path forward and will “pursue all paths to bring relacorilant to Cushing’s patients.” But the reality is that this is now years away, and investor patience for yet another long trial is limited.

Pipeline Prospects: BELLA, MONARCH, EU Approval, and Beyond

Beyond Lifyorli in ovarian cancer, Corcept has several pipeline programs that could reshape the company’s future. Each carries real upside but also real risk.

BELLA – Phase 2b Multi-Arm in Gynecologic Cancers

BELLA (NCT06906341) is an open-label, multi-arm Phase 2 evaluating relacorilant + nab-paclitaxel ± bevacizumab across several gynecologic settings:

• Platinum-resistant ovarian cancer (exploratory expansion beyond ROSELLA).
• Platinum-sensitive ovarian cancer (earlier-line opportunity).
• Endometrial cancer.

If BELLA shows benefit in platinum-sensitive ovarian or endometrial cancer, it could provide label expansion data for Lifyorli and significantly expand the addressable market. Investor timelines suggest initial data could arrive in late 2026 or early 2027. This is a critical catalyst for the bullish case.

MONARCH – Miricorilant in MASH (Phase 2b)

MONARCH (NCT06108219) is a randomized, double-blind, placebo-controlled Phase 2b evaluating miricorilant, another Corcept cortisol modulator, in non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH). The trial is measuring 48-week histologic endpoints (liver fibrosis, steatosis, inflammation).

MASH is a rapidly growing indication with high unmet need. If miricorilant shows meaningful histologic improvement, Corcept could have a second-wave asset in a much larger market than ovarian cancer. However, MASH trials are long, and histologic endpoints require liver biopsies, limiting the patient population. Initial data are unlikely before 2026–2027.

EU Approval for Lifyorli (ROSELLA)

Corcept has also submitted a Marketing Authorization Application (MAA) to the European Medicines Agency for Lifyorli in platinum-resistant ovarian cancer. EU decisions typically take 12–18 months, so an approval in late 2026 or 2027 is plausible. Dual approval (U.S. + EU) would turn Lifyorli into a global oncology franchise and significantly expand market opportunity.

Other Programs: Dazucorilant in ALS, Nenocorilant, and Early-Stage Modulators

Corcept has a portfolio of selective cortisol modulators in various stages of development. Dazucorilant in ALS (Lou Gehrig’s disease) is in Phase 2. A successful ALS program could be huge — ALS is an orphan indication but carries high unmet need and strong advocacy. However, ALS trials are long and hard; early phase data from ALS programs are typically not expected before 2027–2028.

Korlym and the Teva Situation: Managing Erosion

Korlym (mifepristone 300 mg) remains Corcept’s cash engine. In Q3 2025, Korlym revenue was still robust, and Corcept generated meaningful profit margins. The Federal Circuit decision on February 19 does not shut off Korlym immediately; generic erosion is a gradual process, typically playing out over 2–5 years depending on payer acceptance and patient willingness to switch.

The Court Decision: What Changed

The Federal Circuit affirmed that Teva’s generic Korlym does not infringe Corcept’s U.S. Patents 10,195,214 or 10,842,800, which cover methods of co-administering Korlym with strong CYP3A inhibitors (like ketoconazole). The court reasoned that:

• There is no evidence that physicians historically or will routinely practice the specific high-dose co-administration regimen described in the patents.
• Modern alternatives (like osilodrostat) and standard medical practice make the patented approach unlikely to become standard of care.
• Teva’s label does not mandate the patented method, so induced infringement is not satisfied.

Translation: Teva’s generic is legally clear to operate, and Corcept has no remaining patent leverage to slow market penetration. Over the next 2–3 years, payers will likely shift patients from branded Korlym to generic, especially since the therapeutic effect is identical. Price concessions on branded Korlym (to retain patients) are likely.

Managed Decline vs. Collapse

Corcept is not facing a “cliff” on Korlym revenues. The company will likely manage a gradual erosion:

• Patient inertia: Some patients will stay on branded Korlym due to brand loyalty, insurance co-pay advantages, or physician preference.
• Price optimization: Corcept may offer rebates or patient assistance to defend share.
• Specialty pharma advantage: Korlym is a specialty drug; Corcept’s commercial infrastructure, patient education, and endocrinologist relationships provide some cushion against generic substitution.

The realistic scenario is that Korlym revenue remains significant for 3–5 years but declines at 5–15% per year as generic market share grows. By 2030–2031, Korlym may represent only 20–30% of Corcept’s revenue, down from today’s ~60–70%. This is manageable if Lifyorli ramps as expected and pipeline programs generate value.

Financials and Runway

One of the reasons CORT did not collapse below $30 despite the December 31 CRL and February patent loss is that the company’s balance sheet is genuinely strong. Corcept is not a cash-burning pre-revenue biotech; it’s a profitable specialty pharma.

What This Means

With $524M in cash and low burn, Corcept has runway to:

• Run the new Cushing confirmatory trial (estimated $50–150M+ cost).
• Complete BELLA and MONARCH Phase 2b programs.
• Launch and ramp Lifyorli commercially in the U.S. and EU.
• Invest in pipeline programs.
• Continue share repurchases or strategic M&A if desired.

All of this without a capital raise. Even if Korlym declines faster than expected, Lifyorli launch revenue should begin to offset that decline within 12–18 months. This is a material competitive advantage relative to cash-strapped biotechs forced to dilute shareholders with emergency equity raises.

Risk to the Thesis

The risk is not “cash crunch,” but rather “value destruction via over-investment” or “capital allocation mistakes.” If Corcept invests heavily in a Cushing trial that takes longer than expected, or if Lifyorli uptake disappoints, the company could see margins compress and cash burn accelerate. By 2028–2029, if neither Lifyorli nor BELLA/MONARCH have generated meaningful revenue, cash position could become a concern. But that’s a multi-year risk, not an imminent one.

Ownership, Short Interest, Insiders, and Institutions

Short Interest

As of early March 2026, CORT had roughly 10–11 million shares sold short, representing approximately 11–12% of the public float. Short interest ratio (days to cover) hovered around 14 days. This is elevated, signaling that a meaningful number of sophisticated investors are betting against the company.

The short thesis has evolved: early shorts bet against Cushing approval; after the CRL, shorts bet on further downside given the loss of near-term revenue. Today’s approval will likely force some short covering (hence the 40% rally), but a residual short position persists among those worried about Lifyorli execution, Korlym erosion, and the class action lawsuits.

Insider Ownership

CEO Joseph Belanoff and other insiders own a meaningful stake — estimates range from 11–25% depending on the data provider. High insider ownership is generally positive (alignment with shareholders), but can also create governance concerns if the founder has outsized control. In Belanoff’s case, he has been with Corcept since its founding and has navigated multiple inflection points, so the market generally views insider ownership as a positive signal.

Institutional Base

Institutional ownership is approximately 70–75%, with major holders including:

• BlackRock
• Vanguard Group
• Ingalls & Snyder
• Renaissance Technologies
• Various mutual funds and hedge funds

The cap table is therefore a mix of long institutional investors, meaningful insider stakes, and a material (but not extreme) short position. This creates a balanced market structure, which should support relative price stability as Lifyorli is commercialized.

Management and Execution Risk

Joseph K. Belanoff, M.D. – CEO and Founder

Joseph Belanoff co-founded Corcept in 1998 and remains the CEO and Board Chair. He holds a B.A. from Amherst College and an M.D. from Columbia University. His track record includes:

• Building Corcept from inception to a publicly traded, profitable specialty pharma.
• Bringing Korlym to FDA approval in 2012 and scaling it to a ~$600M+ annual revenue franchise.
• Maintaining a balanced pipeline across multiple indications (endocrinology, oncology, neurology, metabolism).
• Preserving company independence while managing patent litigation and generic threats.

Critics point to communication tone issues — some felt Belanoff and IR were overly optimistic about Cushing approval odds, which created surprise when the CRL landed. Management has also taken a combative stance with Teva and the FDA on certain issues, which may have burned bridges. However, the market generally views Belanoff as competent and committed to building long-term shareholder value.

Execution Risk Going Forward

The key execution risks are:

• Lifyorli commercialization: Can Corcept’s sales force (relatively small) effectively penetrate the ovarian cancer market? Will payers reimburse at prices that support the revenue thesis? Early commentary from analysts suggests initial uptake will be monitored closely in 2026–2027.
• BELLA readout: If BELLA fails or shows no benefit in earlier-line ovarian or endometrial cancer, the story deflates significantly.
• Cushing trial design: If the FDA does not accept Corcept’s proposed trial design, further delays are possible.
• Pipeline execution: MONARCH, ALS, and other programs need to generate data on schedule. Delays cascade.

The Class Action Elephant in the Room

As of late March 2026, multiple securities class action lawsuits have been filed against Corcept and certain executives (including CEO Belanoff) on behalf of shareholders who purchased CORT between October 31, 2024 and December 30, 2025 (the “Class Period”). Lead plaintiff deadlines are April 21, 2026.

Core Allegations

The lawsuits allege that Corcept and management:

• Made materially false or misleading statements about the likelihood of FDA approval for relacorilant in Cushing’s syndrome.
• Failed to disclose material adverse information, including FDA concerns about the efficacy data package, which management was allegedly aware of during pre-submission meetings.
• In particular, the FDA allegedly informed Corcept “on several occasions” during pre-submission meetings of concerns about “the adequacy of the clinical development program” and warned to “expect significant review issues.”

The complaints cite the December 31 CRL announcement, which caused CORT to plummet from $70 to $35 (−50%), as the triggering event for the class.

Likelihood and Impact

Securities class actions in biotech are common and often settle for small percentages of the alleged loss. However, this particular case has some teeth because:

• The FDA’s January 30, 2026 updated CRL explicitly stated that the agency had warned Corcept in pre-submission meetings, giving plaintiffs a contemporaneous document suggesting scienter (intent to mislead).
• The 50% single-day drop and the gap between management commentary and the CRL outcome create a clear causation story.
• Corcept is profitable and well-capitalized, making it an attractive target for plaintiffs’ counsel.

Expected outcome: Corcept will likely settle this case for $50–200M (rough estimate based on biotech precedents), either through insurance or a direct settlement. This is material but not existential for a company with $524M in cash. However, it adds overhang and legal cost to management’s plate.

Retail Sentiment – From Collapse Despair to Approval Euphoria

Retail sentiment on Stocktwits, Reddit, and X/Twitter has swung dramatically over the past 12 weeks.

Post-CRL (Dec 31 – early Jan): Panic and anger. “Rug pull,” “management lied,” “Cushing was overhyped” were common refrains. Many bag holders (who bought near the $100+ highs) were venting. Retail shorts and daytrade bears were celebrating.

Post-Federal Circuit (Feb 19): Further capitulation. “Korlym is dead,” “two strikes and you’re out” narratives dominated. Retail sentiment shifted to “wait for capitulation” or “abandon ship.”

Post-FDA Approval (March 25 – today): Euphoria and short-covering rallies. “Lifyorli is a real drug,” “FDA approval proves the science,” “back in the game” are now the dominant themes. Some bag holders are covering losses; opportunists who bought at $30 are celebrating 40% gains.

Note: Retail sentiment observations are based on community commentary patterns on Stocktwits, Reddit, and X/Twitter. These are not professional research and should be treated as anecdotal market psychology, not fundamental fact.

Bull, Base, and Bear Scenarios

The base case is most likely: Corcept has a real product in Lifyorli and genuine pipeline optionality, but the Cushing setback means the company must prove it can execute in oncology — a new space for them — and sustain profitability as Korlym declines. This is an execution-dependent story, not a “sure thing.”

Bottom Line – From Ashes to Opportunity

Corcept’s March 25, 2026 FDA approval of Lifyorli is a genuine validation of the company’s science and a redemptive moment after three months of devastation. Lifyorli is the first SGRA approved in oncology, it addresses a real unmet need in platinum-resistant ovarian cancer, and the ROSELLA trial data are solid. The stock’s 40% reaction is justified.

But the approval does not reset all risks. Cushing is now a multi-year sidetrack, Korlym will face generic erosion, and Lifyorli must prove it can ramp in a competitive market. The class action lawsuits add legal overhang and management credibility questions. The balance sheet is strong, but it is not infinite; over-investment in the wrong programs or slower-than-expected revenue ramps could create cash concerns by 2028–2029.

In plain terms: Corcept is no longer a “one-product or bust” story, but it is not yet a “worry-free growth story” either. It is an execution story. The next 12–24 months — Lifyorli launch, BELLA readout, MONARCH progress, and Korlym trajectory — will determine whether today’s approval is the start of a multi-decade renaissance or a temporary reprieve before a long decline.

Investors should watch for:

• Q2 2026 earnings (late May): First guidance for Lifyorli commercial revenue and Korlym performance post-generic launch.
• BELLA interim data (late 2026 or 2027): Early readout could signal label expansion potential.
• Cushing trial design decision (mid-2026): FDA acceptance of trial plan confirms timeline.
• Korlym erosion rate (2026–2027): How fast does generic market share grow? The pace is critical.
• Class action settlement (2026–2027): What are the financial and governance implications?